Velarion · Company Intelligence
Compensation Brief
Fiscal year 2025 · Filings through 2026-07-29

Editas Medicine (EDIT)

Fiscal year 2025 executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.

$2,353,655
Gilmore O'Neill total, FY2025
CEO pay percentile vs peers
CEO-to-median pay ratio
83.89%
Say-on-pay support, latest vote
Companies that benchmark against EDIT
9 companies name EDIT as a compensation peer

Each company listed discloses EDIT in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named EDIT in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.

01

Summary Compensation Table — fiscal year 2025

Named executive officerSalaryBonusStock awardsOption awardsNon-equity incentivePension / NQDCAll otherTotal
Gilmore O'Neill$686,574$0$0$1,282,937$375,164$0$8,980$2,353,655
President and Chief Executive Officer
Linda Burkly517,16900441,417206,993010,8101,176,389
Executive Vice President and Chief Scientific Officer
Amy Parison394,20200266,135154,04807,270821,655
Senior Vice President and Chief Financial Officer

A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.

Three-year trend — total compensation per named executive

Named executive officerFY2025 totalFY2024 totalFY2023 totalΔ FY20242025
Gilmore O'Neill$2,353,655
Linda Burkly1,176,389
Amy Parison821,655

Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.

02

Equity transactions since the proxy statement was filed

Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.

InsiderRoleTransaction dateCodeSharesPriceValueSecuritySource
Amy ParisonSVP, Chief Financial Officer2026-06-03D464$3$1,253CommonForm 4 ↗
Gilmore O'NeillDirector2026-06-03D15,380341,543CommonForm 4 ↗
Linda BurklyEVP, CHIEF SCIENTIFIC OFFICER2026-06-03D73131,975CommonForm 4 ↗
Elliott M. LevyDirector2026-06-17A51,70000Derivative, Class A CommonForm 4 ↗
Bernadette ConnaughtonDirector2026-06-17A51,70000Derivative, Class A CommonForm 4 ↗
Jessica HopfieldDirector2026-06-17A51,70000Derivative, Class A CommonForm 4 ↗
David ScaddenDirector2026-06-17A51,70000Derivative, Class A CommonForm 4 ↗
Andrew HirschDirector2026-06-17A51,70000Derivative, Class A CommonForm 4 ↗
Linda BurklyEVP, CHIEF SCIENTIFIC OFFICER2026-07-28D4,928313,158CommonForm 4 ↗

Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.

03

Grants of plan-based awards — fiscal year 2025

ExecutiveAwardGrant dateThresholdTargetGrantedMaximumGrant-date fair value
Amy ParisonOPTION$266,135
Gilmore O'NeillOPTION1,282,937
Linda BurklyOPTION441,417
03b

Vehicle mix — grant-date fair value by award type

Named executive officerTime-vested (RSU)Performance-vested (PSU)Options / SARs% performance-vested
Amy Parison$0$0$266,1350.0%
Gilmore O'Neill001,282,9370.0%
Linda Burkly00441,4170.0%

% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.

04

Outstanding equity awards at fiscal year-end 2025

ExecutiveAwardShares unvestedExercise priceMarket value unvested
Linda BurklyRSU30,112$61,730
Amy ParisonOption1,9038.72
Gilmore O'NeillOption672,7501.72
Linda BurklyOption53,6358.66
Gilmore O'NeillRSU73,519150,714
Amy ParisonOption118,2581.72
Amy ParisonOption4,47515.83
Linda BurklyRSU22,58346,295
Linda BurklyRSU13,95028,598
Amy ParisonRSU6,45713,237
Linda BurklyOption41,8509.92
Amy ParisonRSU1,4913,057
Gilmore O'NeillRSU15,62532,031
Linda BurklyOption70,0001.72
Amy ParisonOption28,8930.98
Linda BurklyOption223,5191.72
Amy ParisonOption42,8801.72
Amy ParisonOption9,6869.92
Gilmore O'NeillRSU130,700267,935
Gilmore O'NeillRSU85,000174,250
Linda BurklyRSU49,600101,680
Gilmore O'NeillRSU21,66344,409
Gilmore O'NeillOption175,0001.72
Amy ParisonRSU1,2282,599
Gilmore O'NeillOption220,5569.92
Gilmore O'NeillOption118,77611.54
Gilmore O'NeillOption46,8758.72
05

Incentive-plan design — the Compensation Discussion & Analysis

Our compensation programs are designed to attract and retain qualified and talented executives, motivate such executives to achieve our business goals and reward them for short- and long-term performance.

CEO STI target (% of salary)60%
CEO LTI target (% of salary)
Independent consultantPearl Meyer & Partners, LLC
Clawback policyTrue
Anti-hedgingTrue
Anti-pledgingTrue
06

Say-on-pay — recent advisory votes

Meeting yearMeeting dateForAgainstAbstainSupportOutcome
20262026-06-1732,914,2586,322,885212,58783.89%Passed
20252025-05-2916,066,73810,241,052221,69061.07%Passed
20242024-05-3038,609,8282,769,887205,78893.31%Passed
20232023-06-0127,178,0823,102,043215,68589.76%Passed
20222022-06-0927,094,1524,523,649332,69685.69%Passed
20212021-06-0331,762,8762,875,374207,96191.7%Passed

Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year's compensation.

Say-on-pay — history, company's computation

Meeting yearMeeting dateApproval — company's computation
20262026-06-1783.89%a
20252025-05-2961.07%b
20242024-05-3093.31%c

a. Approved under the standard stated in the filing — “Abstentions and broker non-votes will not be counted as votes cast or voted on any of the proposals.”.

b. Approved under the standard stated in the filing — “Abstentions and broker non-votes will not be counted as votes cast or voted on any of the proposals.”.

c. Approved under the standard stated in the filing — “Abstentions and broker non-votes will not be counted as votes cast or voted on any of the proposals.”.

Approval percentages are the company's own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.

07

CEO pay ratio

Ratio (CEO : median employee)
CEO total compensation
Median employee compensation
08

Director compensation — fiscal year 2025

DirectorCash feesStock awardsOption awardsNon-equity incentiveAll otherTotal
Jessica Hopfield, Ph.DIndependent · Board Chair · Audit · Nominating/Governance (Chair)$93,750$0$52,463$0$0$146,213
Andrew HirschIndependent · Audit (Chair) · Compensation66,250052,46300118,713
Bernadette ConnaughtonIndependent · Compensation (Chair) · Nominating/Governance60,000052,46300112,463
Elliott Levy, M.DIndependent · Audit48,750052,46300101,213
David T. Scadden, M.DIndependent · Compensation47,500052,4630099,963
Gilmore O'Neill, M.B., M.M.ScEmployee director00000
09

Board fee structure and ownership guideline

Annual cash retainer$40,000
Annual equity retainer$300,000
Per board meeting fee
Committee chair fees (audit / comp / nom-gov)18,750 / 15,000 / 10,000
Stock ownership guideline
09b

Total cost of the board

ComponentFY2025
Cash retainers and fees$316,250
Equity awards (grant-date value)$0
All other compensation$0
Total cost of the board$316,250

Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.

10

Disclosed peer group — fiscal year 2025

The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.

10a

Peer reciprocity

Of the companies Editas Medicine names as compensation peers, which name it back in their own disclosed peer groups. A peer set the market reciprocates reads differently from one selected in a single direction.

Reciprocity shown where the peer's own current proxy has been read — each mark is cited in the register to that peer's filing. A dash means the peer's current proxy was read and names no reciprocal group including Editas Medicine.

10b

Chief executive pay against the peer group

Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.

RankCompanyFYChief executiveSalaryStock awardsOption awardsNon-equity incentiveTotal
1Solid Biosciences Inc.2025Alexander Cumbo$650,988$2,318,275$1,792,397$0$5,223,442
2Lyell Immunopharma, Inc.2025Lynn Seely690,173186,8062,907,551414,0004,222,265
3Prime Medicine, Inc.2025Allan Reine606,21202,828,798402,0003,894,187
4Nkarta, Inc.2025Paul Hastings674,384236,2501,711,957344,9472,978,038
5TScan Therapeutics, Inc.2025Gavin MacBeath665,00001,982,800139,6502,801,450
6Voyager, Inc.2025Alfred Sandrock674,903611,900843,900361,9172,508,370
7Cabaletta Bio, Inc.2025Steven Nichtberger659,55001,266,978446,9822,401,555
8Editas Medicine2025Gilmore O'Neill686,57401,282,937375,1642,353,655
9Fate Therapeutics, Inc.2025Bahram Valamehr600,00001,283,868360,0002,248,568
10Caribou Biosciences, Inc.2025Rachel Haurwitz667,534192,818654,54101,840,965
Tenaya Therapeutics, Inc.not in coverage universe
Neurogene Inc.not in coverage universe
Adicet Bio, Inc.not in coverage universe
Lexeo Therapeutics, Inc.not in coverage universe

Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.

10c

Incentive design against the same peers

CompanyAnnual incentive payoutLong-term vehicle mixPSU measures include TSRCompensation consultant
Editas Medicine91%Options 100not disclosedPearl Meyer & Partners, LLC
Adicet Bio, Inc.not disclosednot disclosednot disclosednot disclosed
Cabaletta Bio, Inc.114.49%Options 100not disclosedAon
Caribou Biosciences, Inc.85%not disclosednot disclosedAlpine Rewards, LLC
Fate Therapeutics, Inc.100%Options 100NoAon's Human Capital Solutions practice (Radford)
Lexeo Therapeutics, Inc.not disclosednot disclosednot disclosednot disclosed
Lyell Immunopharma, Inc.100%not disclosedNoAlpine
Neurogene Inc.not disclosednot disclosednot disclosednot disclosed
Nkarta, Inc.not disclosednot disclosednot disclosedAon Consulting, Inc.
Prime Medicine, Inc.120%Options 100not disclosedAlpine Rewards
Solid Biosciences Inc.100%not disclosedNoRadford (AON Hewitt)
Tenaya Therapeutics, Inc.not disclosednot disclosednot disclosednot disclosed
TScan Therapeutics, Inc.not disclosedOptions 100not disclosednot disclosed
Voyager, Inc.97.5%not disclosedNoAlpine Rewards, LLC

Read from each company's Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company's filing does not state the item.

11

Source register

Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.

#SupportsDocumentFiledAccessionLocation in document
1Section 01, Gilmore O'NeillDEF 14A2026-04-280001650664-26-000037Section “2025 Summary Compensation Table”. As printed: 2,353,655. Filing ↗machine: t42 · r2 · c12 · span 545455–545464
2Section 01, Linda BurklyDEF 14A2026-04-280001650664-26-000037Section “2025 Summary Compensation Table”. As printed: 1,176,389. Filing ↗machine: r4 · c21 · span 550598–550607
3Section 01, Amy ParisonDEF 14A2026-04-280001650664-26-000037Section “2025 Summary Compensation Table”. As printed: 821,655. Filing ↗machine: r6 · c21 · span 553910–553917
4Section 03, Amy Parison OPTIONDEF 14A2026-04-280001650664-26-000037Section “TABLE OF CONTENTS EXECUTIVE COMPENSATION” · grants of plan-based awards table. Filing ↗machine: t42 · r6 · c6 · span 552889–552896
5Section 03, Gilmore O'Neill OPTIONDEF 14A2026-04-280001650664-26-000037Section “TABLE OF CONTENTS EXECUTIVE COMPENSATION” · grants of plan-based awards table. Filing ↗machine: t42 · r2 · c6 · span 544258–544267
6Section 03, Linda Burkly OPTIONDEF 14A2026-04-280001650664-26-000037Section “TABLE OF CONTENTS EXECUTIVE COMPENSATION” · grants of plan-based awards table. Filing ↗machine: t42 · r4 · c6 · span 549576–549583
7Section 07, pay ratio10-K2026-03-090001650664-26-000017Section “CEO Pay Ratio”. As printed: —. Filing ↗
8Section 08, Jessica Hopfield, Ph.DDEF 14A2026-04-280001650664-26-000037Section “Director Compensation”. As printed: 146,213. Filing ↗machine: t50 · r4 · c5 · span 785301–785308
9Section 08, Andrew HirschDEF 14A2026-04-280001650664-26-000037Section “Director Compensation”. As printed: 118,713. Filing ↗machine: t50 · r3 · c5 · span 784005–784012
10Section 08, Bernadette ConnaughtonDEF 14A2026-04-280001650664-26-000037Section “Director Compensation”. As printed: 112,463. Filing ↗machine: t50 · r2 · c5 · span 782690–782697
11Section 08, Elliott Levy, M.DDEF 14A2026-04-280001650664-26-000037Section “Director Compensation”. As printed: 101,213. Filing ↗machine: t50 · r5 · c5 · span 786591–786598
12Section 08, David T. Scadden, M.DDEF 14A2026-04-280001650664-26-000037Section “Director Compensation”. As printed: 99,963. Filing ↗machine: t50 · r6 · c5 · span 787886–787892
13Section 08, Gilmore O'Neill, M.B., M.M.ScDEF 14A2026-04-280001650664-26-000037Section “Director Compensation”. As printed: 0. Filing ↗
14Section 02, Amy Parison 2026-06-03Form 42026-06-050001650664-26-000057Insider equity transaction reported since the proxy statement. Filing ↗
15Section 02, Gilmore O'Neill 2026-06-03Form 42026-06-050001650664-26-000056Insider equity transaction reported since the proxy statement. Filing ↗
16Section 02, Linda Burkly 2026-06-03Form 42026-06-050001650664-26-000055Insider equity transaction reported since the proxy statement. Filing ↗
17Section 02, Elliott M. Levy 2026-06-17Form 42026-06-220001650664-26-000068Insider equity transaction reported since the proxy statement. Filing ↗
18Section 02, Bernadette Connaughton 2026-06-17Form 42026-06-220001650664-26-000072Insider equity transaction reported since the proxy statement. Filing ↗
19Section 02, Jessica Hopfield 2026-06-17Form 42026-06-220001650664-26-000071Insider equity transaction reported since the proxy statement. Filing ↗
20Section 02, David Scadden 2026-06-17Form 42026-06-220001650664-26-000069Insider equity transaction reported since the proxy statement. Filing ↗
21Section 02, Andrew Hirsch 2026-06-17Form 42026-06-220001650664-26-000070Insider equity transaction reported since the proxy statement. Filing ↗
22Section 02, Linda Burkly 2026-07-28Form 42026-07-290001650664-26-000076Insider equity transaction reported since the proxy statement. Filing ↗
23Section 06, 2026 voteForm 8-K2026-06-180001650664-26-000063Item 5.07 · say-on-pay result. As reported: 83.89% (votes for as printed: 32,914,258). Filing ↗
24Section 06, 2025 voteForm 8-K2025-06-020001650664-25-000086Item 5.07 · say-on-pay result. As reported: 61.07% (votes for as printed: 16,066,738). Filing ↗
25Section 06, 2024 voteForm 8-K2024-05-310001650664-24-000050Item 5.07 · say-on-pay result. As reported: 93.31% (votes for as printed: 38,609,828). Filing ↗
26Section 03b vehicle mix (computed)ComputedcomputedRSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).machine: formula: sums + PSU ratio
27Section 09b board cost (computed)ComputedcomputedCash 316,250 + equity 0 + all other 0 = 316,250, summed across the director compensation table rows.machine: formula: Σ = 316,250
28Solid Biosciences Inc., Section 10b CEO totalDEF 14A2026-04-230001193125-26-173642CEO total compensation as printed in Solid Biosciences Inc.'s own proxy. As printed: 5,223,442. Filing ↗machine: r2 · c25 · span 472915–472924
29Lyell Immunopharma, Inc., Section 10b CEO totalDEF 14A2026-04-240001140361-26-016686CEO total compensation as printed in Lyell Immunopharma, Inc.'s own proxy. As printed: 4,222,265. Filing ↗machine: r2 · c24 · span 450163–450172
30Prime Medicine, Inc., Section 10b CEO totalDEF 14A2026-04-230001628280-26-026697CEO total compensation as printed in Prime Medicine, Inc.'s own proxy. As printed: 3,894,187. Filing ↗machine: r2 · c42 · span 285179–285188
31Nkarta, Inc., Section 10b CEO totalDEF 14A2026-04-230001140361-26-016403CEO total compensation as printed in Nkarta, Inc.'s own proxy. As printed: 2,978,038. Filing ↗machine: r2 · c27 · span 344226–344235
32TScan Therapeutics, Inc., Section 10b CEO totalDEF 14A2026-04-170001193125-26-160304CEO total compensation as printed in TScan Therapeutics, Inc.'s own proxy. As printed: 2,801,450. Filing ↗machine: r2 · c27 · span 220378–220387
33Voyager, Inc., Section 10b CEO totalDEF 14A2026-04-280001104659-26-050297CEO total compensation as printed in Voyager, Inc.'s own proxy. As printed: 2,508,370. Filing ↗machine: t9 · r1 · c47 · span 370852–370861
34Cabaletta Bio, Inc., Section 10b CEO totalDEF 14A2026-04-280001193125-26-183557CEO total compensation as printed in Cabaletta Bio, Inc.'s own proxy. As printed: 2,401,555. Filing ↗
35Editas Medicine (subject), Section 10b CEO totalDEF 14A2026-04-280001650664-26-000037CEO total compensation as printed in Editas Medicine's own proxy. As printed: 2,353,655. Filing ↗machine: t42 · r2 · c12 · span 545455–545464
36Fate Therapeutics, Inc., Section 10b CEO totalDEF 14A2026-04-240001193125-26-177094CEO total compensation as printed in Fate Therapeutics, Inc.'s own proxy. As printed: 2,248,568. Filing ↗machine: r2 · c31 · span 391551–391560
37Caribou Biosciences, Inc., Section 10b CEO totalDEF 14A2026-04-240001619856-26-000022CEO total compensation as printed in Caribou Biosciences, Inc.'s own proxy. As printed: 1,840,965. Filing ↗machine: r2 · c39 · span 189876–189885
38Section 10a, Voyager, Inc. reciprocityDEF 14A0001104659-26-050297Voyager, Inc. names Editas Medicine in its own disclosed peer group (read from its most recent proxy). Filing ↗